The DOI matches its Crossref record; 239 of the 239 references it cites were found in a registry or an index.
Molecular pathways in non-alcoholic fatty liver disease
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological change characterized by the accumulation of triglycerides in hepatocytes and has frequently been associated with obesity, type 2 diabetes mellitus, hyperlipidemia, and insulin resistance. It is an increasingly recognized condition that has become the most common liver disorder in developed countries, affecting over one-third of the population and is associated with increased cardiovascular- and liver-related mortality. NAFLD is a spectrum of disorders, beginning as simple steatosis. In about 15% of all NAFLD cases, simple steatosis can evolve into non-alcoholic steatohepatitis, a medley of inflammation, hepatocellular injury, and fibrosis, often resulting in cirrhosis and even hepatocellular cancer. However, the molecular mechanism underlying NAFLD progression is not completely understood. Its pathogenesis has often been interpreted by the "double-hit" hypothesis. The primary insult or the "first hit" includes lipid accumulation in the liver, followed by a "second hit" in which proinflammatory mediators induce inflammation, hepatocellular injury, and fibrosis. Nowadays, a more complex model suggests that fatty acids (FAs) and their metabolites may be the true lipotoxic agents that contribute to NAFLD progression; a multiple parallel hits hypothesis has also been suggested. In NAFLD patients, insulin resistance leads to hepatic steatosis via multiple mechanisms. Despite the excess hepatic accumulation of FAs in NAFLD, it has been described that not only de novo FA synthesis is increased, but FAs are also taken up from the serum. Furthermore, a decrease in mitochondrial FA oxidation and secretion of very-low-density lipoproteins has been reported. This review discusses the molecular mechanisms that underlie the pathophysiological changes of hepatic lipid metabolism that contribute to NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–239 of 239
Videla, L. A., & Pettinelli, P. (2012) · PPAR Research · doi:10.1155/2012/107434 · Cited by 79
Buqué, X., Martínez, M. J., Cano, A., Miquilena-Colina, M. E., García‐Monzón, C., Aspichueta, P., & Ochoa, B. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m001966 · Cited by 78
Ooi, E. M. M., Watts, G. F., Sprecher, D. L., Chan, D. C., & Barrett, P. H. R. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1131 · Cited by 77
The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis
VanWagner, L. B., & Rinella, M. E. (2011) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x11403809 · Cited by 77
LESMANA, C. R. A., HASAN, I., BUDIHUSODO, U., GANI, R. A., KRISNUHONI, E., AKBAR, N., & LESMANA, L. A. (2009) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2009.00386.x · Cited by 76
Zhou, Y., Li, Y., Nie, Y., Yang, H., Qi, Z., Huang, J. V., Shi, S., Lai, X., & Huang, H. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.06144.x · Cited by 76
Auguet, T., Terra, X., Porras, J. A., Orellana‐Gavaldà, J. M., Martínez, S., Aguilar, C., Lucas, A., Pellitero, S., Hernández, M., Castillo, D. D., et al. (2012) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.11.006 · Cited by 71
Self-citationDegrace, P., Moindrot, B., Mohamed, I., Gresti, J., Du, Z., Chardigny, J., Sébédio, J., & Clouet, P. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600140-jlr200 · Cited by 70
Influence of Visfatin on Histopathological Changes of Non-alcoholic Fatty Liver Disease
Aller, R., de Luis, D. A., Izaola, O., Sagrado, M. G., Conde, R., Velasco, M. C., Alvarez, T., Pacheco, D., & González, J. M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0539-9 · Cited by 68
Jourdan, T., Demizieux, L., Gresti, J., Djaouti, L., Gaba, L., Vergès, B. L., & Degrace, P. (2011) · Hepatology · doi:10.1002/hep.24733 · Cited by 68
Das, S., Seth, R. K., Kumar, A., Kadiiska, M. B., Michelotti, G. A., Diehl, A. M., & Chatterjee, S. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00235.2013 · Cited by 67
Arden, C., Petrie, J. L., Tudhope, S. J., Al‐Oanzi, Z. H., Claydon, A. J., Beynon, R. J., Towle, H. C., & Agius, L. (2011) · Diabetes · doi:10.2337/db11-0061 · Cited by 66
Chanda, D., Kim, D., Li, T., Kim, Y., Koo, S., Lee, C., Chiang, J. Y. L., & Choi, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.224352 · Cited by 65
Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management
Yan, E., Durazo, F. A., Tong, M. J., & Hong, K. M. (2007) · Nutrition Reviews · doi:10.1111/j.1753-4887.2007.tb00315.x · Cited by 63
Ge, F., Zhou, S., Hu, C., Lobdell, H., & Berk, P. D. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00434.2009 · Cited by 62
Tilg, H. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208929 · Cited by 60
Martin, G., Nemoto, M., Gelman, L., Geffroy, S., Najïb, J., Fruchart, J., Roevens, P. W. M., de Martinville, B., Deeb, S. S., & Auwerx, J. H. (2000) · Genomics · doi:10.1006/geno.2000.6191 · Cited by 60
Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategies
Huang, Y. Y., Gusdon, A. M., & Qu, S. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-171 · Cited by 56
Increased Hepatic and Circulating Interleukin-6 Levels in Human Nonalcoholic Steatohepatitis
Wieckowska, A. M. D., Papouchado, B. G., Li, Z., López, R., Zein, N. N., & Feldstein, A. E. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.02161_17.x · Cited by 54
Krušinová, E., & Pelikánová, T. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.023 · Cited by 53
Auinger, A., Valenti, L. V. C., Pfeuffer, M., Helwig, U., Herrmann, J. E., Fracanzani, A. L., Dongiovanni, P., Fargion, S. R., Schrezenmeir, J., & Rubin, D. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1267186 · Cited by 53
Kashireddy, P. V. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.06.004 · Cited by 52
Faulds, M. H., Zhao, C., & Dahlman‐Wright, K. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2010.07.003 · Cited by 49
Use of statins in patients with liver disease
Tandra, S., & Vuppalanchi, R. (2009) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-009-0028-2 · Cited by 48
Berk, P. D. (2008) · Hepatology · doi:10.1002/hep.22632 · Cited by 46
Serum fatty acid binding protein 4, free fatty acids, and metabolic risk markers
Karakas, S. E., Almario, R. U., & Kim, K. (2009) · Metabolism · doi:10.1016/j.metabol.2009.02.024 · Cited by 45
Rao, M. S., Papreddy, K., Musunuri, S., & Okonkwo, A. M. (2002) · PubMed · Cited by 44
Harnois, D. M. (2011) · Yearbook of Gastroenterology · doi:10.1016/j.ygas.2011.07.031 · Cited by 43
Treatment of patients with non-alcoholic fatty liver disease: Current views and perspectives
Federico, A., Trappoliere, M., & Loguercio, C. (2006) · Digestive and Liver Disease · doi:10.1016/j.dld.2006.04.009 · Cited by 38
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Harnois, D. M. (2010) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(10)79533-7 · Cited by 38
Seth, R. K., Das, S., Kumar, A., Chanda, A., Kadiiska, M. B., Michelotti, G. A., Manautou, J. E., Diehl, A. M., & Chatterjee, S. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.10.029 · Cited by 35
Altered distribution of caveolin‐1 in early liver steatosis
Mastrodonato, M., Calamita, G., Rossi, R., Mentino, D., Bonfrate, L., Portincasa, P., Ferri, D., & Liquori, G. E. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02459.x · Cited by 34
CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis
Wasmuth, H. E., & Trautwein, C. (2007) · Hepatology · doi:10.1002/hep.21527 · Cited by 33
Iizuka, K., Takeda, J., & Horikawa, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.100 · Cited by 33
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1050114 · Cited by 23
Maroni, L., Guasti, L., Castiglioni, L., Marino, F., Contini, S., Macchi, V., Leo, A. D., Gaudio, G. V., Tozzi, M., Grandi, A. M., et al. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e318213e526 · Cited by 20
Schinner, S., & Schott, M. (2009) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(09)79329-1 · Cited by 10
Zhang, Y., Yin, L., & Hillgartner, F. B. (2002) · The Research Repository @ WVU (West Virginia University) · Cited by 7
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Leahy, J. L. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79220-5 · Cited by 6
Cited by
Carnitine transport and fatty acid oxidation
Longo, N., Frigeni, M., & Pasquali, M. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.01.023 · Cited by 996
Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2016) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044224 · Cited by 611
Recent insights into the pathogenesis of nonalcoholic fatty liver disease
Arab, J. P., Arrese, M., & Trauner, M. (2018) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043617 · Cited by 573
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
Metadata
- Authors
- Auguet, T., Berlanga, A., Guiu-Jurado, E., & Porras, J. A.
- Venue
- Clinical and Experimental Gastroenterology
- Publisher
- Informa UK Limited
- Published
- 2014-07
- Volume
- 7
- Pages
- 221
- ISSN
- 1178-7023 (ISSN-L)
- OpenAlex
- W1999617321
- Cited by
- 379
- References
- 239
- FWCI
- 29.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.